Literature DB >> 27694925

Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma.

J R Sawyer1,2, E Tian2, J D Shaughnessy3, J Epstein2, C M Swanson1, C Stangeby1, C L Hale1, L Parr1, M Lynn1, G Sammartino1, J L Lukacs1, C Stein2, C Bailey2, M Zangari2, F E Davies2, F Van Rhee2, B Barlogie2, G J Morgan2.   

Abstract

Hyperhaploid clones (24-34 chromosomes) were identified in 33 patients with multiple myeloma (MM), demonstrating a novel numerical cytogenetic subgroup. Strikingly, all hyperhaploid karyotypes were found to harbor monosomy 17p, the single most important risk stratification lesion in MM. A catastrophic loss of nearly a haploid set of chromosomes results in disomies of chromosomes 3, 5, 7, 9, 11, 15, 18, 19 and 21, the same basic set of odd-numbered chromosomes found in trisomy in hyperdiploid myeloma. All other autosomes are found in monosomy, resulting in additional clinically relevant monosomies of 1p, 6q, 13q and 16q. Hypotriploid subclones (58-68 chromosomes) were also identified in 11 of the 33 patients and represent a duplication of the hyperhaploid clone. Analysis of clones utilizing interphase fluorescence in situ hybridization (iFISH), metaphase FISH and spectral karyotyping identified either monosomy 17 or del17p in all patients. Amplification of 1q21 was identified in eight patients, demonstrating an additional high-risk marker. Importantly, our findings indicate that current iFISH strategies may be uninformative or ambiguous in the detection of these clones, suggesting this patient subgroup maybe underreported. Overall survival for patients with hyperhaploid clones was poor, with a 5-year survival rate of 23.1%. These findings identify a distinct numerical subgroup with cytogenetically defined high-risk disease.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27694925      PMCID: PMC6005364          DOI: 10.1038/leu.2016.253

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  40 in total

1.  Hypodiploidy is a major prognostic factor in multiple myeloma.

Authors:  N V Smadja; C Bastard; C Brigaudeau; D Leroux; C Fruchart
Journal:  Blood       Date:  2001-10-01       Impact factor: 22.113

2.  Clinical implication of centrosome amplification in plasma cell neoplasm.

Authors:  Wee J Chng; Greg J Ahmann; Kim Henderson; Rafael Santana-Davila; Philip R Greipp; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; Shaji Kumar; S Vincent Rajkumar; John A Lust; Robert A Kyle; Steven R Zeldenrust; Suzanne R Hayman; Rafael Fonseca
Journal:  Blood       Date:  2005-12-22       Impact factor: 22.113

3.  In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.

Authors:  Erming Tian; Jeffrey R Sawyer; Christoph J Heuck; Qing Zhang; Frits van Rhee; Bart Barlogie; Joshua Epstein
Journal:  Genes Chromosomes Cancer       Date:  2014-03-17       Impact factor: 5.006

4.  Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.

Authors:  Jeffrey R Sawyer; Erming Tian; Christoph J Heuck; Donald J Johann; Joshua Epstein; Charles M Swanson; Janet L Lukacs; Regina Lichti Binz; Marian Johnson; Gael Sammartino; Maurizio Zangari; Faith E Davies; Frits van Rhee; Gareth J Morgan; Bart Barlogie
Journal:  Blood       Date:  2015-05-05       Impact factor: 22.113

5.  Minor clone provides a reservoir for relapse in multiple myeloma.

Authors:  F Magrangeas; H Avet-Loiseau; W Gouraud; L Lodé; O Decaux; P Godmer; L Garderet; L Voillat; T Facon; A M Stoppa; G Marit; C Hulin; P Casassus; M Tiab; E Voog; E Randriamalala; K C Anderson; P Moreau; N C Munshi; S Minvielle
Journal:  Leukemia       Date:  2012-08-09       Impact factor: 11.528

6.  Curing myeloma at last: defining criteria and providing the evidence.

Authors:  Bart Barlogie; Alan Mitchell; Frits van Rhee; Joshua Epstein; Gareth J Morgan; John Crowley
Journal:  Blood       Date:  2014-10-07       Impact factor: 22.113

7.  Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival.

Authors:  Hervé Avet-Loiseau; Michel Attal; Loic Campion; Denis Caillot; Cyrille Hulin; Gerald Marit; Anne-Marie Stoppa; Laurent Voillat; Marc Wetterwald; Brigitte Pegourie; Eric Voog; Mourad Tiab; Anne Banos; Jerome Jaubert; Didier Bouscary; Margaret Macro; Brigitte Kolb; Catherine Traulle; Claire Mathiot; Florence Magrangeas; Stephane Minvielle; Thierry Facon; Philippe Moreau
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

Review 8.  The genetic architecture of multiple myeloma.

Authors:  Gareth J Morgan; Brian A Walker; Faith E Davies
Journal:  Nat Rev Cancer       Date:  2012-04-12       Impact factor: 60.716

9.  Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project.

Authors:  H Avet-Loiseau; B G M Durie; M Cavo; M Attal; N Gutierrez; J Haessler; H Goldschmidt; R Hajek; J H Lee; O Sezer; B Barlogie; J Crowley; R Fonseca; N Testoni; F Ross; S V Rajkumar; P Sonneveld; J Lahuerta; P Moreau; G Morgan
Journal:  Leukemia       Date:  2012-10-03       Impact factor: 11.528

10.  Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping.

Authors:  J R Sawyer; J L Lukacs; N Munshi; K R Desikan; S Singhal; J Mehta; D Siegel; J Shaughnessy; B Barlogie
Journal:  Blood       Date:  1998-12-01       Impact factor: 22.113

View more
  8 in total

Review 1.  Evolutionary biology of high-risk multiple myeloma.

Authors:  Charlotte Pawlyn; Gareth J Morgan
Journal:  Nat Rev Cancer       Date:  2017-08-24       Impact factor: 60.716

Review 2.  Multiple Myeloma: Molecular Pathogenesis and Disease Evolution.

Authors:  Michael Heider; Katharina Nickel; Marion Högner; Florian Bassermann
Journal:  Oncol Res Treat       Date:  2021-11-08       Impact factor: 2.825

3.  Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multi-parametric flow cytometry method.

Authors:  Surbhi Sidana; Dragan Jevremovic; Rhett P Ketterling; Nidhi Tandon; Angela Dispenzieri; Morie A Gertz; Patricia T Greipp; Linda B Baughn; Francis K Buadi; Martha Q Lacy; William Morice; Curtis Hanson; Michael Timm; David Dingli; Suzanne R Hayman; Wilson I Gonsalves; Prashant Kapoor; Robert A Kyle; Nelson Leung; Ronald S Go; John A Lust; S Vincent Rajkumar; Shaji K Kumar
Journal:  Am J Hematol       Date:  2019-01-08       Impact factor: 10.047

4.  Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM.

Authors:  Marietta S Truger; Johannes Duell; Xiang Zhou; Larissa Heimeshoff; Anna Ruckdeschel; Mara John; Angela Riedel; Sebastian Hüper; Jessica Peter; Wencke Walter; Larissa Haertle; Manja Meggendorfer; Max S Topp; Andreas Rosenwald; Matteo Claudio Da Via; Niccolo Bolli; Niels Weinhold; Hermann Einsele; Claudia Haferlach; K Martin Kortüm; Leo Rasche
Journal:  Blood Adv       Date:  2021-10-12

Review 5.  Germline Risk Contribution to Genomic Instability in Multiple Myeloma.

Authors:  Siegfried Janz; Fenghuang Zhan; Fumou Sun; Yan Cheng; Michael Pisano; Ye Yang; Hartmut Goldschmidt; Parameswaran Hari
Journal:  Front Genet       Date:  2019-05-08       Impact factor: 4.599

Review 6.  Genetic Abnormalities in Multiple Myeloma: Prognostic and Therapeutic Implications.

Authors:  Ignacio J Cardona-Benavides; Cristina de Ramón; Norma C Gutiérrez
Journal:  Cells       Date:  2021-02-05       Impact factor: 6.600

Review 7.  Genetic Predictors of Mortality in Patients with Multiple Myeloma.

Authors:  Hamza Hassan; Raphael Szalat
Journal:  Appl Clin Genet       Date:  2021-04-29

8.  Hyperhaploid karyotypes in multiple myeloma.

Authors:  Jeffrey R Sawyer; Gareth J Morgan
Journal:  Oncotarget       Date:  2017-09-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.